OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	171
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	166
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	131
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	122
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	119
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	106
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	105
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	100
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	98
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	94
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	93
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	93
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	87
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	80
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	76
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	75
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	75
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	74
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	70
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	67
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	67
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	65
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	64
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	61
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	61

Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	60
Dynamic reciprocal relationships between cognitive and functional declines along the Alzheimer’s disease continuum in the prospective COGICARE study	56
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	55
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	55
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6	55
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	52
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	52
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	51
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	51
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	50
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	50
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	49
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	49
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	49
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC	49
Serum neurofilament light chain level as a predictor of cognitive stage transition	49
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	48
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	48
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	48
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	48
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	48
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	47
Cross-cultural effects of reminiscence therapy on life satisfaction and autobiographical memory of older adults: a pilot study across Mexico and Spain	47